Axena Health, a provider of an FDA-cleared smartphone app-connected vaginal motion sensor intended to improve the lives of women with pelvic floor disorder, raised $25 million in Series A funding.
AXA IM Alts, through its Global Healthcare Private Equity Strategy, led the investment round.
The investment will support the company in scaling up its Leva Pelvic Health System, a prescription digital therapeutic offering at-home treatment for urinary and chronic fecal incontinence in women.
The U.S. Food and Drug Administration approved the therapeutic system to treat stress, mixed and mild-to-moderate urgency urinary incontinence (including the overactive bladder) in women and for first-line treatment of chronic fecal incontinence in women.
Commenting on the funding news, Eileen Maus, the ECO of Axena Health, said: “Axena Health is a women-founded, women-funded, women-focused company.” “We’re grateful to extend this solution globally, where an even greater number of women are silently enduring the significant medical, social and economic effects of incontinence. We look forward to working with our investors to support what we believe is a first-of-its-kind commitment to bring an affordable digital health treatment for incontinence to women regardless of geography.”
“We’re intently focused on combining novel technology, rigorous, peer-reviewed data and excellence in patient support to shine a light on what remains a vastly underserved area of women’s health,” said Samantha Pulliam, Chief Medical Officer at Axena Health.
“The Leva Pelvic Health System can help women ease the burden of incontinence at home, on their own schedule, and allow them to re-engage with the activities that make them feel whole. We’re excited to have the opportunity to deliver these benefits to more women here in the U.S. and soon throughout the world.”
According to our funding database, wearable sensor-powered health monitoring device startups have raised more than $10 billion in funding to date. More recently, SiBionics, a provider of sensor-powered wearable devices system to track blood sugar levels in real-time, raised $71.7 million in Series D funding. In another deal, Zoe, a provider of a sensor-enabled wearable arm patch to track blood sugar in real-time, raised £25 million in funding led by Accomplice with participation from Balderton Capital, Ahren, Daphni, and L Catterton.
